Relmada Therapeutics (RLMD) Shares Outstanding (2012 - 2026)

Relmada Therapeutics (RLMD) has reported Shares Outstanding (Entity) for 15 consecutive years, with $86.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Shares Outstanding (Entity) rose 160.9% year-over-year to $86.6 million; the TTM figure through Mar 2026 stood at $86.6 million (up 160.9% YoY), while the FY2025 annual figure was $39.5 million, up 30.84% from the prior year.
• Shares Outstanding (Entity) improved to $86.6 million in Q1 2026 per RLMD's latest filing, from $39.5 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $86.6 million in Q1 2026 and bottomed at $13.4 million in Q1 2022.
• Historically, Shares Outstanding (Entity) has averaged $33.5 million across 5 years, with a median of $30.2 million in 2024.
• Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) retreated 19.77% — and 2026, when it jumped 160.9%.
• Relmada Therapeutics' Shares Outstanding (Entity) stood at $30.1 million in 2022, then changed by 0.0% to $30.1 million in 2023, then rose by 0.25% to $30.2 million in 2024, then surged by 30.84% to $39.5 million in 2025, then soared by 119.35% to $86.6 million in 2026.
• Business Quant data shows RLMD's Shares Outstanding (Entity) at $86.6 million in Q1 2026, $39.5 million in Q4 2025, and $33.2 million in Q3 2025.